Abstract
Rats were administered daily for 8 days with increasing doses (2-12 mg/kg/day) of delta9-tetrahydrocannabinol (delta9-THC) and than challenged with different doses of SR141716A, an antagonist of cannabinoid receptors. SR141716A dose dependently reduced dialysate dopamine (DA) in the nucleus accumbens shell and precipitated a physical withdrawal syndrome. No such effects were obtained after administration of SR141716A to saline controls.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Behavior, Animal / drug effects
-
Cannabinoids / antagonists & inhibitors
-
Dopamine / metabolism
-
Dopamine / physiology*
-
Dronabinol / pharmacology*
-
Dronabinol / toxicity
-
Hallucinogens / pharmacology*
-
Hallucinogens / toxicity
-
Male
-
Microdialysis
-
Nucleus Accumbens / drug effects*
-
Nucleus Accumbens / physiology
-
Piperidines / pharmacology
-
Pyrazoles / pharmacology
-
Rats
-
Rats, Sprague-Dawley
-
Receptors, Cannabinoid
-
Receptors, Drug / antagonists & inhibitors
-
Rimonabant
-
Substance Withdrawal Syndrome / physiopathology
-
Substance-Related Disorders / physiopathology*
Substances
-
Cannabinoids
-
Hallucinogens
-
Piperidines
-
Pyrazoles
-
Receptors, Cannabinoid
-
Receptors, Drug
-
Dronabinol
-
Rimonabant
-
Dopamine